atazanavir teva 150 mg kapsułki twarde
teva pharmaceuticals polska sp. z o.o. - atazanaviri sulfas - kapsułki twarde - 150 mg
atazanavir teva 200 mg kapsułki twarde
teva pharmaceuticals polska sp. z o.o. - atazanaviri sulfas - kapsułki twarde - 200 mg
atazanavir teva 300 mg kapsułki twarde
teva pharmaceuticals polska sp. z o.o. - atazanaviri sulfas - kapsułki twarde - 300 mg
nulibry
tmc pharma (eu) limited - fosdenopterin hydrobromide dihydrate - metal metabolism, inborn errors - inne przewodu pokarmowego i przemianę materii narzędzia, - nulibry is indicated for the treatment of patients with molybdenum cofactor deficiency (mocd) type a.
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - okulistyka - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
hemlibra
roche registration limited - emicizumab - hemofilia - antykrościeryczne - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra mogą być używane we wszystkich grupach wiekowych.
durfenta 12 mcg/h system transdermalny, plaster
lavipharm s.a. - fentanylum - system transdermalny, plaster - 12 mcg/h
durfenta 25 mcg/h system transdermalny, plaster
lavipharm s.a. - fentanylum - system transdermalny, plaster - 25 mcg/h
durfenta 50 mcg/h system transdermalny, plaster
lavipharm s.a. - fentanylum - system transdermalny, plaster - 50 mcg/h
durfenta 75 mcg/h system transdermalny, plaster
lavipharm s.a. - fentanylum - system transdermalny, plaster - 75 mcg/h